What's on this Page
What is Vedolizumab
Vedolizumab is a monoclonal antibody that is a specific integrin receptor antagonist. It is used for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease in adult patients.
Treatment with vedolizumab is appropriate for patients who have failed to fully respond to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroid therapy or who are intolerant to or demonstrated dependence on corticosteroids.
Brand Name
Entyvio
Indications
- Crohn’s disease
- ulcerative colitis
For moderately to severely active ulcerative colitis to reduce signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapy
Side Effects
- anaphylactoid reactions
- antibody formation
- arthralgia
- back pain
- bronchospasm
- cough
- dyspnea
- elevated hepatic enzymes
- fatigue
- fever
- flushing
- headache
- hepatic failure
- hepatitis
- infection
- influenza
- jaundice
- leukoencephalopathy
- musculoskeletal pain
- nausea
- new primary malignancy
- pharyngitis
- pruritus
- rash
- sinusitis
Monitoring Parameters
- LFTs
Contraindications
- breast-feeding
- hepatic disease
- human anti-chimeric antibody (HACA)
- immunosuppression
- infants
- infection
- jaundice
- neonates
- pregnancy
- progressive multifocal leukoencephalopathy
- sepsis
- tuberculosis
- vaccination
Interactions
- Adalimumab
- Certolizumab pegol
- Etanercept
- Golimumab
- Infliximab
- Live Vaccines
- Natalizumab
- Tumor Necrosis Factor modifiers